| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.39▲ | 2.36▲ | 2.35▲ | 2.18▲ | 1.92▲ |
| MA10 | 2.38▲ | 2.33▲ | 2.31▲ | 2.01▲ | 2.15▲ |
| MA20 | 2.36▲ | 2.29▲ | 2.28▲ | 1.88▲ | 2.55▼ |
| MA50 | 2.33▲ | 2.20▲ | 2.06▲ | 2.23▲ | 2.64▼ |
| MA100 | 2.29▲ | 2.04▲ | 1.95▲ | 2.68▼ | 4.18▼ |
| MA200 | 2.26▲ | 1.94▲ | 1.97▲ | 2.66▼ | 8.19▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.004▲ | 0.000▼ | 0.087▲ | -0.053▼ |
| RSI | 70.392▲ | 69.431▲ | 74.178▲ | 63.559▲ | 48.701▼ |
| STOCH | 89.444▲ | 95.665▲ | 79.155 | 81.544▲ | 26.051 |
| WILL %R | -21.429▲ | -7.317▲ | -6.977▲ | -2.899▲ | -42.378 |
| CCI | 134.815▲ | 151.551▲ | 160.854▲ | 183.199▲ | -4.898 |
|
Sunday, April 26, 2026 01:24 PM
Following the successful spin-off of its Sandoz generics division in late 2023, Novartis AG (NYSE:NVS) has transformed into a high-margin, pure-play innovative medicines company that is currently ...
|
|
Friday, April 24, 2026 05:46 AM
Novartis (NYSE:NVS) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a favourable opinion recommending approval of Itvisma, an intrathecal gene therapy ...
|
|
Thursday, April 02, 2026 12:29 AM
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/05/26 | 2.28 | 2.42 | 2.21 | 2.40 | 685,113 |
| 05/05/26 | 2.29 | 2.38 | 2.19 | 2.27 | 1,737,487 |
| 04/05/26 | 2.00 | 2.35 | 1.98 | 2.28 | 1,976,460 |
| 01/05/26 | 2.01 | 2.02 | 1.94 | 2.00 | 701,280 |
| 30/04/26 | 1.94 | 1.9999 | 1.86 | 1.97 | 1,098,120 |
| 29/04/26 | 1.90 | 1.90 | 1.79 | 1.84 | 653,023 |
| 28/04/26 | 1.89 | 2.005 | 1.85 | 1.85 | 1,330,004 |
| 27/04/26 | 1.78 | 1.935 | 1.75 | 1.89 | 1,022,138 |
| 24/04/26 | 1.73 | 1.82 | 1.73 | 1.74 | 856,181 |
| 23/04/26 | 1.82 | 1.8393 | 1.7301 | 1.81 | 1,119,084 |
|
|
||||
|
|
||||
|
|